Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Celgene Corporation

Related CELG
Celgene Receives Positive CHMP Opinion For OTEZLA, The First Oral PDE4 Inhibitor For The Treatment Of Patients With Psoriasis And Psoriatic Arthritis
Which Mega Caps Are Buying Their Own Stock?
Yellen Swats Down Biotech, Social Media Stocks (Fox Business)

In a report published Friday, Jefferies reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $104.00 to $114.00.

Jefferies noted, “On its 4Q earnings call, CELG focused details around achieving the 2017 guidance laid out earlier this month. We are raising our price target from $104 to $114 as we are adding modest apremilast to our valuation and raising our expectations for Abraxane penetration in pancreatic cancer following positive Phase 3 data released yesterday.”

Celgene Corporation closed on Thursday at $97.49.

Latest Ratings for CELG

DateFirmActionFromTo
Oct 2014CitigroupMaintainsBuy
Oct 2014Credit SuisseMaintainsOutperform
Sep 2014Cantor FitzgeraldMaintainsBuy

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

Around the Web, We're Loving...

Get Benzinga's Newsletters